drugset / Trial / NCT04160494
D2C7-IT With Atezolizumab for Recurrent Gliomas
Phase 1
Active not recruiting
18 enrolled
Darell Bigner
Genentech, Inc. · collabIstari Oncology, Inc. · collabNational Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase 1 study of atezolizumab in combination with D2C7-IT, a dual-specific monoclonal antibody (mAB) with a high affinity for both EGFRwt- and EGFRvIII-expressing cells, in patients with recurrent World Health Organization (WHO) grade IV malignant glioma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
Timeline
- Start
- 2020-02-25
- Primary completion
- 2024-06-28
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | D2C7-IT | Protein / enzyme biologic | 4613.2 ng/ml | Other |
| Subject | D2C7-IT | Protein / enzyme biologic | 6920 ng/ml | Other |